Recommendations for chronic lymphocytic leukaemia diagnosis and therapy

Abstract

The treatment of chronic lymphocytic leukaemia (CLL) has changed dramatically in recent years. New oral signalling pathway targeted inhibitors have significantly improved the prognosis of patients with CLL. Currently, two main groups of small molecules are used, namely Bruton's tyrosine kinase (BTK) inhibitors and BCL-2 inhibitors. However, the results of new clinical trials directly impacting routine clinical practice are rapidly accumulating. We therefore present updated recommendations for the diagnosis and treatment of CLL, based on a comprehensive analysis of the current literature and following the principles of evidence-based medicine.